Dublin, Feb. 20, 2017 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Proteomics - Technologies, Markets and Companies" to their offering.
This report describes and evaluates the proteomic technologies that will play an important role in drug discovery, molecular diagnostics and practice of medicine in the post-genomic era - the first decade of the 21st century.
Proteomics is providing a better understanding of pathomechanisms of human diseases. Analysis of different levels of gene expression in healthy and diseased tissues by proteomic approaches is as important as the detection of mutations and polymorphisms at the genomic level and may be of more value in designing a rational therapy. Protein distribution / characterization in body tissues and fluids, in health as well as in disease, is the basis of the use of proteomic technologies for molecular diagnostics.
Proteomics will play an important role in medicine of the future which will be personalized and will combine diagnostics with therapeutics. Important areas of application include cancer (oncoproteomics) and neurological disorders (neuroproteomics). The text is supplemented with 44 tables, 28 figures and over 500 selected references from the literature.
The number of companies involved in proteomics has increased remarkably during the past few years. More than 300 companies have been identified to be involved in proteomics and 224 of these are profiled in the report with 456 collaborations.
The markets for proteomic technologies are difficult to estimate as they are not distinct but overlap with those of genomics, gene expression, high throughput screening, drug discovery and molecular diagnostics. Markets for proteomic technologies are analyzed for the year 2016 and are projected to years 2021 and 2026. The largest expansion will be in bioinformatics and protein biochip technologies. Important areas of application are cancer and neurological disorders
Key Topics Covered:
Part I: Technologies & Markets
Executive Summary
1. Basics of Proteomics
2. Proteomic Technologies
3. Protein biochip technology
4. Bioinformatics in Relation to Proteomics
5. Research in Proteomics
6. Pharmaceutical Applications of Proteomics
7. Application of Proteomics in Human Healthcare
8. Oncoproteomics
9. Neuroproteomics
10. Proteomics Markets
11. Future of Proteomics
12. References
Part II: Companies
11. Companies involved in developing proteomics
For more information about this report visit http://www.researchandmarkets.com/research/n9q3zl/proteomics
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Proteomics


Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
Meta Is Building an AI Version of Mark Zuckerberg to Interact With Employees
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
Jefferies Upgrades Starbucks to Hold as China JV Deal Closes and U.S. Business Shows Signs of Recovery
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
Chinese Cars in Europe: Consumer Trust Is Shifting Fast
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 



